Literature DB >> 10672953

Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia.

T Klotz1, M J Mathers, W Bloch, W Nayal, U Engelmann.   

Abstract

BACKGROUND: Nitric oxide (NO) is involved in the physiologic regulation of smooth muscle relaxation in the prostate. Organic nitrates act as NO donors. In this prospective open study we prove the influence of orally given nitrates on micturition.
METHODS: Thirty-two patients underwent a urological medical check-up prior to starting nitrate medication for cardiovascular disease. We examined peak flow rates, residual urine, IPS-score, PSA level and prostate volume. Exact inclusion and exclusion criteria were defined. Fifteen patients suffered from obstructive symptoms, 17 patients reported no subjective micturition problems. Urological re-evaluation was performed two weeks and three months after nitrate medication.
RESULTS: A significant improvement of peak urinary flow rates (+3.1 ml/s; p<0.05), IPS score and significant decrease of residual urine volume (-22 ml; p<0.05) were found in the symptomatic patients. No significant changes of micturition parameters were found in asymptomatic patients. PSA levels and prostate volumes did not change in either groups.
CONCLUSIONS: Organic nitrates influence micturition parameters in patients with obstructive benign prostatic hyperplasia. This might be explained by the known mechanism of NO donation (smooth muscle relaxation) of nitrates. More functional controlled studies are necessary to describe the grade of influence of nitrates on the prostate. Concomitant oral medication with nitrates must be considered as a relevant bias factor on BPH in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672953     DOI: 10.1023/a:1007174102953

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  Heme oxygenase and NO-synthase in the human prostate--relation to adrenergic, cholinergic and peptide-containing nerves.

Authors:  P Hedlund; P Ekström; B Larsson; P Alm; K E Andersson
Journal:  J Auton Nerv Syst       Date:  1997-04-14

2.  Characterization and localization of nitric oxide synthase in the human prostate.

Authors:  A L Burnett; M P Maguire; S L Chamness; D D Ricker; M Takeda; H Lepor; T S Chang
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

3.  Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide.

Authors:  W Bloch; T Klotz; C Loch; G Schmidt; U Engelmann; K Addicks
Journal:  Prostate       Date:  1997-09-15       Impact factor: 4.104

4.  Effects of nitric oxide on human and canine prostates.

Authors:  M Takeda; R Tang; E Shapiro; A L Burnett; H Lepor
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

Review 5.  Nitric oxide-based possibilities for pharmacotherapy.

Authors:  I Pörsti; I Paakkari
Journal:  Ann Med       Date:  1995-06       Impact factor: 4.709

6.  A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia.

Authors:  T Tsujii; H Azuma; T Yamaguchi; H Oshima
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

7.  Nitric oxide synthase activity in the human urogenital tract.

Authors:  I Ehrén; J Adolfsson; N P Wiklund
Journal:  Urol Res       Date:  1994

8.  Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum.

Authors:  W Bloch; T Klotz; P Sedlaczek; J Zumbé; U Engelmann; K Addicks
Journal:  Urol Res       Date:  1998

Review 9.  Nitric oxide: mediator, murderer, and medicine.

Authors:  E Anggård
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

10.  Nitric oxide modulates sympathetic neurotransmission at the prejunctional level.

Authors:  K Addicks; W Bloch; M Feelisch
Journal:  Microsc Res Tech       Date:  1994-10-01       Impact factor: 2.769

View more
  12 in total

Review 1.  Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression.

Authors:  L Zakaria; A G Anastasiadis; R Shabsigh
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 3.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 4.  Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

Authors:  Petter Hedlund
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

Review 5.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.

Authors:  Dong Soo Park; Taek Woo Cho; Yong Kyu Lee; Young Tae Lee; Young Kwon Hong; Woong Ki Jang
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

7.  The effect of intravesical sodium nitroprusside on idiopathic detrusor overactivity.

Authors:  Fatih Tarhan; Erkan Erbay; Bilal Eryildirim; Gökhan Faydaci; Uethur Kuyumcuoğlu
Journal:  Urol Res       Date:  2004-02-07

Review 8.  The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

Authors:  George T Kedia; Stefan Uckert; Udo Jonas; Markus A Kuczyk; Martin Burchardt
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

Review 9.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.